(Q42748426)

6 November 2017

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma (English)

1 reference

6 November 2017

11

1 reference

6 November 2017

C Touzeau

1

1 reference

6 November 2017

C Dousset

2

1 reference

6 November 2017

S Le Gouill

3

1 reference

6 November 2017

D Sampath

4

1 reference

6 November 2017

J D Leverson

5

1 reference

6 November 2017

A J Souers

6

1 reference

6 November 2017

S Maïga

7

1 reference

6 November 2017

M C Béné

8

1 reference

6 November 2017

P Moreau

9

1 reference

6 November 2017

C Pellat-Deceunynck

10

1 reference

6 November 2017

language of work or name

1 reference

17 July 2013

1 reference

6 November 2017

1 reference

6 November 2017

28

1 reference

6 November 2017

210-212

1 reference

6 November 2017

1

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

6 November 2017

start time

17 July 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/leu.2013.216

0 references

cites work

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887407

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887407

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887407

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887407

ABT-737 is highly effective against molecular subgroups of multiple myeloma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887407

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887407

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887407

Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887407

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3887407

Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience

27 May 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2013.216

21 January 2018

Identifiers

DOI

10.1038/LEU.2013.216

1 reference

Dimensions Publication ID

6 November 2017

0 references

1 reference

6 November 2017

1 reference